1. Home
  2. GPMT vs MGNX Comparison

GPMT vs MGNX Comparison

Compare GPMT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPMT
  • MGNX
  • Stock Information
  • Founded
  • GPMT 2015
  • MGNX 2000
  • Country
  • GPMT United States
  • MGNX United States
  • Employees
  • GPMT N/A
  • MGNX N/A
  • Industry
  • GPMT Real Estate Investment Trusts
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPMT Real Estate
  • MGNX Health Care
  • Exchange
  • GPMT Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • GPMT 122.0M
  • MGNX 99.7M
  • IPO Year
  • GPMT 2017
  • MGNX 2013
  • Fundamental
  • Price
  • GPMT $2.75
  • MGNX $1.72
  • Analyst Decision
  • GPMT Buy
  • MGNX Hold
  • Analyst Count
  • GPMT 3
  • MGNX 6
  • Target Price
  • GPMT $3.13
  • MGNX $3.20
  • AVG Volume (30 Days)
  • GPMT 204.3K
  • MGNX 630.9K
  • Earning Date
  • GPMT 11-05-2025
  • MGNX 11-04-2025
  • Dividend Yield
  • GPMT 7.29%
  • MGNX N/A
  • EPS Growth
  • GPMT N/A
  • MGNX N/A
  • EPS
  • GPMT N/A
  • MGNX N/A
  • Revenue
  • GPMT N/A
  • MGNX $165,495,000.00
  • Revenue This Year
  • GPMT N/A
  • MGNX N/A
  • Revenue Next Year
  • GPMT $26.51
  • MGNX N/A
  • P/E Ratio
  • GPMT N/A
  • MGNX N/A
  • Revenue Growth
  • GPMT N/A
  • MGNX 303.47
  • 52 Week Low
  • GPMT $1.61
  • MGNX $0.99
  • 52 Week High
  • GPMT $3.66
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • GPMT 37.65
  • MGNX 50.98
  • Support Level
  • GPMT $2.93
  • MGNX $1.66
  • Resistance Level
  • GPMT $3.03
  • MGNX $1.83
  • Average True Range (ATR)
  • GPMT 0.08
  • MGNX 0.12
  • MACD
  • GPMT -0.04
  • MGNX 0.00
  • Stochastic Oscillator
  • GPMT 0.03
  • MGNX 53.70

About GPMT Granite Point Mortgage Trust Inc.

Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: